You are here: Industry Insights > Zolgensma

News List

Expanded access for Zolgensma following final NICE guidance pharmatimes
July 12, 2021
The National Institute for Health and Care Excellence (NICE) has published its final guidance on Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma.
Zolgensma shows promise in presymptomatic SMA patients pharmatimes
June 22, 2021
Novartis’ gene therapy Zolgensma has shown benefit for presymptomatic spinal muscular atrophy (SMA) patients, according to new data presented at the annual European Academy for Neurology (EAN) virtual congress.
SMC accepts Zolgensma and Rozlytrek for use by NHS Scotland pharmatimes
March 10, 2021
The Scottish Medicines Consortium (SMC) has accepted Novartis Gene Therapies' Zolgensma and Genentech’s Rozlytrek for use by NHS Scotland as part of its March 2021 decisions.
NHS England agrees deal with Novartis for access to SMA gene therapy Zolgensma pharmatimes
March 08, 2021
NHS England and Novartis Gene Therapies have signed a ‘landmark’ agreement that will make Zolgensma available for patients on the NHS.
Financial Report: Novartis contractpharma
November 06, 2020
Pharmaceutical sales up 2% driven by Entresto, Cosentyx and Zolgensma.
REGENXBIO Achieves $80M Novartis Milestone contractpharma
October 29, 2020
Zolgensma, which leverages REGENXBIO's NAV AAV9 vector, reaches $1 billion in sales.
Novartis faces delay in expansion of SMA drug Zolgensma indication pharmaceutical-technology
September 27, 2020
Novartis is facing a delay in expansion of indication for its spinal muscular atrophy (SMA) drug Zolgensma (onasemnogene abeparvovec).
AveXis Receives EC Approval, Activates “Day One” Access Spinal Muscular Atrophy Gene Therapy americanpharmaceuticalreview
May 26, 2020
AveXis, a Novartis company, announced the European Commission (EC) granted conditional approval for Zolgensma® (onasemnogene abeparvovec) ...
Novartis firm AveXis gets EC nod for Zolgensma to treat spinal muscular atrophy pharmaceutical-business-review
May 21, 2020
Novartis company AveXis has secured conditional approval from the European Commission (EC) for its Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).
Novartis’ AveXis gets EC conditional approval for Zolgensma pharmaceutical-technology
May 20, 2020
Novartis subsidiary AveXis has received conditional approval from the European Commission (EC) for Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).

Previous page 1 2 3 4 Next page